Yannis M Paulus1,2, Joan L Jefferys1, Barbara S Hawkins1, Adrienne W Scott3,4. 1. Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. 2. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA. 3. Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. ascott28@jhmi.edu. 4. , 600 North Wolfe Street, Maumenee #719, Baltimore, MD, 21287-92272, USA. ascott28@jhmi.edu.
Abstract
PURPOSE: To determine changes in quality of life measures when choroidal neovascularization (CNV) developed in the second eye of patients with initially unilateral neovascular age-related macular degeneration (AMD). METHODS: We analyzed responses to the 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), 36-item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS) at baseline, and prior to and following second eye CNV diagnosis in 92 participants enrolled in two Submacular Surgery Trials. Paired t-tests for sample sizes over 30 and Wilcoxon signed-rank tests for sample sizes <30 were performed to compare scores. RESULTS: CNV development resulted in statistically and clinically significant changes in responses to 20 of 39 NEI-VFQ items, indicating visual function decline during a mean interval of 25 months. Little difference was noted between baseline scores and prior to CNV diagnosis, which averaged 8.9 months duration. Subscales demonstrated a statistically significant decline in general vision, near activities, distance activities, social functioning, role difficulties, dependency, and driving. There were minimal changes in the HADS and SF-36 scales. CONCLUSION: CNV development in the second eye had a dramatic effect on visual functioning based on patient responses to the NEI-VFQ questionnaire. Our investigation is believed to be the first study using data collected prospectively to demonstrate vision-related quality of life changes that resulted from development of CNV in AMD patients.
PURPOSE: To determine changes in quality of life measures when choroidal neovascularization (CNV) developed in the second eye of patients with initially unilateral neovascular age-related macular degeneration (AMD). METHODS: We analyzed responses to the 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), 36-item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS) at baseline, and prior to and following second eye CNV diagnosis in 92 participants enrolled in two Submacular Surgery Trials. Paired t-tests for sample sizes over 30 and Wilcoxon signed-rank tests for sample sizes <30 were performed to compare scores. RESULTS: CNV development resulted in statistically and clinically significant changes in responses to 20 of 39 NEI-VFQ items, indicating visual function decline during a mean interval of 25 months. Little difference was noted between baseline scores and prior to CNV diagnosis, which averaged 8.9 months duration. Subscales demonstrated a statistically significant decline in general vision, near activities, distance activities, social functioning, role difficulties, dependency, and driving. There were minimal changes in the HADS and SF-36 scales. CONCLUSION: CNV development in the second eye had a dramatic effect on visual functioning based on patient responses to the NEI-VFQ questionnaire. Our investigation is believed to be the first study using data collected prospectively to demonstrate vision-related quality of life changes that resulted from development of CNV in AMDpatients.
Entities:
Keywords:
Age-related macular degeneration; Choroidal neovascularization; National Eye Institute Visual Function Questionnaire; Quality of Life; Second eyes; Submacular Surgery Trials
Authors: Michael A Singer; Carl C Awh; SriniVas Sadda; William R Freeman; Andrew N Antoszyk; Pamela Wong; Lisa Tuomi Journal: Ophthalmology Date: 2012-02-04 Impact factor: 12.079
Authors: Kristina B Lindsley; Susan Hutfless; Barbara S Hawkins; Jill F Blim; Dan Roberts; Timothy W Olsen; Flora Lum; Kay Dickersin Journal: JAMA Ophthalmol Date: 2018-11-01 Impact factor: 7.389
Authors: Jimmy T Le; Elvira Agrón; Tiarnan D L Keenan; Traci E Clemons; Willa D Brenowitz; Kristine Yaffe; Emily Y Chew Journal: Alzheimers Dement Date: 2021-11-10 Impact factor: 16.655
Authors: Tien Yin Wong; Paolo Lanzetta; Francesco Bandello; Bora Eldem; Rafael Navarro; Monica Lövestam-Adrian; Anat Loewenstein Journal: Retina Date: 2020-04 Impact factor: 3.975